Introduction. The problem of safe pharmacotherapy for vascular cognitive impairment (VCI) in patients aged 60 and over is a leading one due to the increasing life expectancy of the population. VCI associated with cerebrovascular diseases is common among geriatric syndromes. Due to multimorbidity, patients of the “silver age” often experience polypharmacy, which can lead to decreased activity in daily life, side effects and adverse drug interactions. Additionally, age-related involutive processes in older patients require increasing drug dosages and constant monitoring of vital signs and laboratory findings. Therefore, it is important to use drugs with a favorable safety profile and good tolerability in older and oldest-old patients in real clinical practice. A review of the results of multicenter, double-blind, placebo-controlled, randomized clinical trials on the safety of Prospekta for the treatment of VCI in patients over 60 confirmed the absence of significant differences in the number of adverse events (AEs) and serious AEs when taking Prospekta and placebo. No clinically significant deviations were found in laboratory parameters, nor were there any negative effects of Prospekta on vital signs, and no negative drug interactions with other basic therapies have been recorded for Prospekta.Conclusion: Prospekta is a safe drug for the treatment of VCI in older and oldest-old patients and can be recommended in geriatric practice without the risk of negative impact on geriatric syndromes.